Table 2 Association between PKC‐δ expression and clinicopathological variables for the breast cancer patient series.
| Variable | Patient no | PKC‐δ positive | PKC‐δ negative | p‐Value |
|---|---|---|---|---|
| ER status | ||||
| Negative | 28 | 13 | 15 | 0.77 |
| Positive | 42 | 21 | 21 | |
| Total | 70 | |||
| Site of disease | ||||
| Locally advanced | 27 | 12 | 15 | 0.65 |
| Metastatic disease | 42 | 21 | 21 | |
| Total | 69 | |||
| Menopausal status | ||||
| Premenopausal | 21 | 10 | 11 | 0.98 |
| Postmenopausal | 48 | 23 | 25 | |
| Total | 69 | |||
| Tumour grade | ||||
| Grade 1 or 2 | 29 | 14 | 15 | 0.95 |
| Grade 3 | 40 | 19 | 21 | |
| Total | 69 | |||
| Quality of response to therapy at 6 months | ||||
| CR/PR/SD | 25 | 17 | 8 | 0.015* |
| PD | 45 | 17 | 28 | |
| Total | 70 | |||
| Endocrine response in ER+ disease | ||||
| CR/PR/SD | 24 | 16 | 8 | 0.013* |
| PD | 18 | 5 | 13 | |
| Total | 42 |
PKC, protein kinase C; ER, oestrogen receptor; CR, complete response; PR, partial response; SD, static disease; PD, progressive disease.
statistically significant (p<0.05)